论文部分内容阅读
近些年来,无论是从治疗的角度还是从发病原理的角度,血小板功能活性在急性冠脉综合征(acute coronary syndrome,ACS)中的地位越来越受到人们的关注。因此,抗血小板治疗是ACS治疗中的一个重要内容。血小板糖蛋白Ⅱb/Ⅲa(GPⅡb/Ⅲa)受体拮抗剂的问世已成为抗血小板治疗中的一个重
In recent years, the function of platelet has drawn more and more attention in acute coronary syndrome (ACS) both from the perspective of treatment and from the perspective of pathogenesis. Therefore, antiplatelet therapy is an important part of ACS treatment. The advent of platelet glycoprotein Ⅱb / Ⅲa (GPⅡb / Ⅲa) receptor antagonists has become a heavy antiplatelet therapy